Drugs and FDA
FDA approves Gazyva for adults with primary membranous nephropathy
In a 142-person study, complete remission at week 104 was higher with Gazyva than tacrolimus, 36% versus 6%, the FDA said.

The FDA approved Gazyva (obinutuzumab) to induce remission of proteinuria in adults with primary membranous nephropathy who are at risk of disease progression. The agency said it is the first drug approved specifically to treat adults with the condition.
The approval was based on the MAJESTY study, which enrolled 142 adults and compared Gazyva with tacrolimus over a main study period of 104 weeks. At week 104, complete remission of proteinuria was achieved by 36% of patients in the Gazyva group and 6% in the tacrolimus group, according to the FDA. Gazyva’s label has a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. The most common side effects in the study were infusion-related reactions and upper respiratory tract infection.


